Difficulty: Medium
Average Score: 84%
Practice
A primary care physician is treating several patients with hypertension and chronic angina. Which of the following patient subsets would best benefit from treatment with ranolazine?
Correct answer
C
Rationale
Ranolazine is a unique antianginal medication that primarily acts by inhibiting the late inward sodium current in cardiac muscle cells, leading to reduced intracellular calcium levels and improved myocardial relaxation. The correct choice, option C, a 65-year-old man with chronic angina who has failed other therapies, is the best candidate for ranolazine treatment.
This patient subset would benefit from ranolazine because it is specifically indicated for the treatment of chronic angina in patients who have not achieved adequate symptom relief with other antianginal therapies like beta-blockers, calcium channel blockers, or nitrates. Ranolazine can be used as adjunctive therapy in such cases to further improve angina symptoms and exercise tolerance.
Option A, the 53-year-old man with acute-onset angina, would not be the best candidate for ranolazine as it is not indicated for acute angina attacks. Rapid-acting agents like nitroglycerin are preferred in this situation. Option B, the 62-year-old man with atrial fibrillation and acute-onset angina, would also not benefit significantly from ranolazine alone, especially given the presence of atrial fibrillation which may require specific management. Option D, the 72-year-old man with acute angina in the emergency department, would require immediate intervention with nitroglycerin or other fast-acting antianginal medications rather than ranolazine.
In an educational context, understanding the specific indications of cardiovascular drugs like ranolazine is crucial for healthcare providers to make informed treatment decisions. It is essential to consider factors such as patient characteristics, clinical presentation, and previous treatment responses when selecting the most appropriate therapy to optimize patient outcomes and safety.
This patient subset would benefit from ranolazine because it is specifically indicated for the treatment of chronic angina in patients who have not achieved adequate symptom relief with other antianginal therapies like beta-blockers, calcium channel blockers, or nitrates. Ranolazine can be used as adjunctive therapy in such cases to further improve angina symptoms and exercise tolerance.
Option A, the 53-year-old man with acute-onset angina, would not be the best candidate for ranolazine as it is not indicated for acute angina attacks. Rapid-acting agents like nitroglycerin are preferred in this situation. Option B, the 62-year-old man with atrial fibrillation and acute-onset angina, would also not benefit significantly from ranolazine alone, especially given the presence of atrial fibrillation which may require specific management. Option D, the 72-year-old man with acute angina in the emergency department, would require immediate intervention with nitroglycerin or other fast-acting antianginal medications rather than ranolazine.
In an educational context, understanding the specific indications of cardiovascular drugs like ranolazine is crucial for healthcare providers to make informed treatment decisions. It is essential to consider factors such as patient characteristics, clinical presentation, and previous treatment responses when selecting the most appropriate therapy to optimize patient outcomes and safety.